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Binary complexAbstract A simple and sensitive spectrophotometric method has been established for the determi-
nation of clemastine hydrogen fumarate (I), desloratadine (II), losartan potassium(III) and moxep-
ril HCl(IV) based on binary complex formation with eosin. The method does not involve solvent
extraction through the use of a non-ionic surfactant (methylcellulose). The color of the produced
complex was measured at 552, 549 nm for (I), (II) while was measured at 540 nm for (III) and
(IV). Appropriate conditions were established for the color reaction between eosin and the studied
drugs to obtain maximum sensitivity. Under the proposed conditions, the method is applicable over
concentration range of 1.25–11.25, 0.31–2.81, 2.5–20 and 1.25–15 lg/ml for (I), (II), (III) and (IV),
respectively. The molar absorptivity (e), sandell sensitivity, detection (LOD) and quantitation limits
(LOQ) are calculated. Unlike other reported ion-pair techniques, the suggested methods have the
advantage of being applicable for the determination of the four drugs in their pharmaceutical dos-
age forms without prior extraction with excellent recoveries.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Clemastine (I) used as the hydrogen fumarate in hay fever, rhi-
nitis, allergic skin conditions, and pruritus. It causes drowsi-
ness; few procedures are described for its determination
including spectrophotometry (Clementina, 2008; Hassan
et al., 2008; El Ragehy et al., 1995), HPLC (Jinlong and
Jianguo, 2007; Viola et al., 2005). Desloratadine (II) an orally
active major metabolite of the nonsedating antihistamine
loratadine is a selective, potent, peripheral H1 receptor antag-
onist. Very few visible spectrophotometric methods have been
described for its determination (Patel et al., 2004; Nahed et al.,
2007). Also, liquid chromatography (El-Sherbiny et al., 2007;
Jun et al., 2009) technique has been described.
S542 S.S. Abd El-Hay et al.Losartan potassium(III) is a highly selective, orally active,
non-peptide angiotensin II receptor antagonist indicated for
the treatment of hypertension. Determination of Losartan
has been carried out by HPLC (Choi et al., 2008; Obando
et al., 2008; Budi et al., 2009). However, few spectrophotomet-
ric methods have been reported for its analysis (Ibrahim, 2005;
Thomas et al., 2007). Moexipril HCl (IV) is a new potent orally
active non-sulfhydryl angiotensin-converting enzyme (ACE)
inhibitor which is used for the treatment of hypertension and
congestive heart failure. Few analytical methods have been
developed for the determination of moexipril, including deriv-
ative spectrophotometric (Erturk et al., 2003) and spectropho-
tometric methods (El-Shanwani et al., 2008a). RP-HPLC has
been developed for the simultaneous determination of moexip-
ril (El-Shanwani et al., 2008b).
Suitable organic dyes such as eosin were used for determi-
nation of many pharmaceutical compounds either spectropho-
tometry through the formation of binary or ternary complexes
(Rahman and Rahman, 2011; Gouda et al., 2008; Walash
et al., 2007) or spectroﬂuorimetry (Ibrahim et al., 2011; Rah-
man et al., 2009; Rahman and Haque, 2008) or by using both
spectrophotometry and spectroﬂuorimetry (Omar, 2010; Abd-
ellatef, 2007).
Here, for the ﬁrst time, eosin was applied to react with
clemastine hydrogen fumarate (I), desloratadine (II), losartan
potassium (III) and moxepril HCl (IV) presenting a rapid
and sensitive assay procedure for the studied drugs in pure
and in pharmaceutical formulations. The proposed method
can be used in laboratories where modern and expensive appa-
ratus, such as that required for GLC or HPLC is not available
in most quality control laboratories.
2. Experimental
2.1. Apparatus
Spectrophotometric measurements were carried out using a
Shimadzu recording spectrophotometer UV 1800 equipped
with 10 mm matched quartz cells.Table 1 Characteristic parameters for the reaction of studied drug
Parameter Clemastine hydrogen fumarate
kmax (nm) 552
Beers law limits (lg/ml) 1.25–11.25
Vol and conc of methyl cellulose 0.5 ml–0.5%
Vol and conc of eosin 1 ml–0.2%
Buﬀer PH 3.7
Buﬀer vol 1.5
Temp. (C) 25 ± 5
Time (min) 5
Regression equationb
Slope (b) 0.0706
Intercept (a) 0.1574
Correlation coeﬃcient (r2) 0.9998
LOD (lg/ml) 0.72
LOQ (lg/ml) 2.39
Sandell sensitivity (lg cm2) 0.01
e (·105) (L mol1 cm1) 0.53
a Average of three experiments.
b A= a+ bcDigital analyzer pH meter (USA) was set to check pH val-
ues of acetate buffer solutions.
2.2. Materials and reagents
Clemastine hydrogen fumarate was kindly supplied by
Novartis pharmaceutical company (Cairo, Egypt). Its pharma-
ceutical preparations Tavegyl tablets (labeled to contain
1 mg clemastine per tablet) and Tavegyl ampoules (labeled
to contain 2 mg clemastine per 2 mL) were obtained from
the local drugstore.
Desloratadine was kindly supplied by Minapharm pharma-
ceutical company (Cairo, Egypt). Its pharmaceutical prepara-
tion Desa tablets (labeled to contain 5 mg desloratadine
per tablet) were obtained from the local drugstore.
Losartan potassium was kindly supplied by Amoun phar-
maceutical company (Obor, Egypt). Its pharmaceutical prepa-
ration Losar tablets (labeled to contain 50 mg losartan
potassium per tablet) were obtained from the local drugstore.
Moexipril hydrochloride was kindly supplied by Minap-
harm pharmaceutical company (Cairo, Egypt). Its pharmaceu-
tical preparation Primox tablets (labeled to contain 15 mg
moexipril hydrochloride (IV) per tablet) were obtained from
the local drugstore.
Eosin (El-Nasr chemical company, Egypt) was prepared as
0.1%, 0.2% solution in distilled water.
Acetate buffer pH 2.8, 3.7 (British Pharmacopoeia, 2007).
Methylcellulose, 0.3%, 0.5% w/v.
All other chemicals and reagents used were of analytical
grade and all solutions were prepared with double distilled
water.
2.3. Standard solutions
2.3.1. Preparation of iosartan potassium and moxepril HCl
standard solutions
Stock working solutions were prepared to contain 0.5 mg/ml,
dissolved in distilled water then the volumes were completed
to 50 ml with distilled water in 50 ml volumetric ﬂasks.s with Eosin.a
Desloratadine Losartan potassium Moexipril HCl
549 540 540
0.31–2.81 2.5–20 1.25–15
0.5 ml–0.3% 0.5 ml–0.5% 0.5 ml–0.5%
2 ml–0.1% 1 ml–0.1% 1 ml–0.1%
2.8 2.8 2.8
1 0.2 0.5
50 60 25 ± 5
10 5 10
0.228 0.035 0.0447
0.1138 0.1323 0.1105
0.9999 0.9998 0.9998
0.9 0.82 0.75
3 2.73 2.51
0.003 0.02 0.014
0.96 0.25 0.36
Figure 1 Absorption curves of 11.25 lg/ml clemastine hydrogen
fumarate, 2.81 lg/ml desloratadine, 20 lg/ml losartan potassium,
15 lg/ml moxepril HCl with eosin.
Figure 4 Effect of temperature on absorbance of 10 lg/ml
clemastine hydrogen fumarate, 2.81 lg/ml desloratadine, 20 lg/ml
losartan potassium and 15 lg/ml moxepril HCl.
Figure 3 Effect of eosin volume on absorbance of 10 lg/ml
clemastine hydrogen fumarate, 2.81 lg/ml desloratadine, 20 lg/ml
losartan potassium and 15 lg/ml moxepril HCl .
Determination of clemastine hydrogen fumarate, desloratadine, losartan potassium and moxepri S5432.3.2. Preparation of clemastine hydrogen fumarate and
desloratadine standard solutions
Stock working solutions were prepared to contain 0.5 mg/ml,
dissolved in least amount of methanol (3 ml) and then the vol-
umes were completed to 50 ml with distilled water in 50 ml vol-
umetric ﬂasks.
Working solutions of lower concentrations were prepared
by appropriate dilutions of the standard solutions.Figure 2 Effect of buffer volume on the ion pair complex
formation between eosin and 11.25 lg/ml clemastine hydrogen
fumarate, 2.81 lg/ml desloratadine, 20 lg/ml losartan potassium,
15 lg/ml moxepril HCl.
Figure 5 Stability of the ion pair complex formed between eosin
and 11.25 lg/ml clemastine hydrogen fumarate, 2.81 lg/ml desl-
oratadine, 20 lg/ml losartan potassium and 15 lg/ml moxepril
HCl.2.3.3. Preparation of methyl cellulose
Methyl cellulose was prepared by dissolving the appropriate
amount in w/v hot water (80 C) with stirring for 10 min then
chilling to 5 C.
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S544 S.S. Abd El-Hay et al.2.4. General procedures
To different aliquots of standard solutions [equivalent to
(0.0125–0.1125), (0.0031–0.0281), (0.025–0.2), (0.0125–0.15)]
mg of (I), (II), (III) and (IV), speciﬁc volumes of eosin
(0.1%, 0.2% w/v) followed by speciﬁed volumes of acetate buf-
fer of certain pHs then 0.5 ml methyl cellulose (0.3%, 0.5%
w/v) were added except for moxepril HCl, methyl cellulose
added at ﬁrst followed by acetate buffer PH 2.8. The contents
were left for the speciﬁed time at certain temperatures as stated
in Table 1.
Then the mixtures were diluted with distilled water and the
absorbencies were measured at 552, 549 nm for (I), (II) while
was measured at 540 nm for (III) and (IV) against a reagent
blank prepared in the same manner.
2.5. Procedure for pharmaceutical formulations
2.5.1. For tablets
A accurately weighted quantity of the well mixed powders
were dissolved in distilled water except for (I) and (II) which
were extracted with methanol (3 ml), then the volumes were
completed to the mark with distilled water in 25 ml calibrated
ﬂasks, ﬁltered and the assay was completed as under general
procedure.
2.5.2. For tavegyl ampoule
Accurate volume of tavegyl vial equivalent to 6.25 mg of clem-
astine hydrogen fumarate was measured, completed to 50 mlFigure 6 Continuous variation plot for clemastine hydrogen
fumarate, desloratadine (1.56 · 104 M), losartan potassium and
moxepril HCl (3.125 · 104 M) with eosin (1.56 · 104 and
3.125 · 104 M, respectively). T
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Determination of clemastine hydrogen fumarate, desloratadine, losartan potassium and moxepri S545with double distilled water and the procedure was completed
as under general procedure.
2.6. Stoichiometric relationship
Job’s method of continuous variations (Rose, 1964) was
employed using equimolar (1.56 · 104 M) standard solutions
of clemastine hydrogen fumarate, desloratadine and (3.125 ·
104 M) of losartan potassium, moxepril HCl with eosin
(1.56 · 104 and 3.125 · 104 M, respectively).
A series of solutions were prepared in which the total
volume of drugs and eosin was kept at 6.0 mL then diluted
to volume in 10-mL calibrated ﬂask with distilled water follow-
ing the above mentioned procedure.T
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.3. Results and discussion
The four studied drugs reacted with eosin through an ion-pair
salt formation, forming a reddish orange chromophore with
kmax at 552, 549 nm for (I), (II) while was measured at
540 nm for (III) and (IV) (Fig. 1).
To optimize the assay parameters, the effects of pH, reac-
tion time, effect of temperature, type, concentration and vol-
ume of surfactant, eosin concentration and volume, order of
addition of reactants were studied.
3.1. Effect of pH on the ion-pair formations
In order to establish the optimum pH value, different volumes
of acetate buffer solutions of different pHs (1.08–6) were
examined. The highest absorbance values were obtained at
pH 2.8 for drugs (II), (III), (IV) or at pH 3.7 for (I). Further-
more, the amount of buffer added varied from 0.1–2 ml and
the optimum volume was found to be 1, 0.2, 0.5 ml for (II),
(III) and (IV) and 1.5 ml for (I) to give the highest absorbance
values (Fig. 2).
3.2. Effect of type and concentration of surfactant
The effect of surfactants on the absorbance of the solution of
the binary complex was examined using various dispersing
agents, such as sodium lauryl sulfate, methylcellulose, Tween
80, and brij. Among the surfactants studied, best results were
obtained in the presence of methylcellulose.
The optimum results were obtained using 0.5 ml methyl cel-
lulose 0.5% for (I), (III) and (IV) and 0.5 ml of 0.3% for (II).
3.3. Effect of eosin concentration, volume
When various concentrations of eosin were added to the stud-
ied drugs (0.05–0.5% w/v), it was found that the ion-pair for-
mation was optimized using 1 ml eosin 0.1% w/v for (III),
(IV), and 2 ml for (II) while using 1 ml 0.2% w/v for (I)
(Fig. 3).
3.4. Effect of time and temperature
The optimum reaction time was determined by following the
color development from ambient temperature 25 ± 5 C to
70 ± 5 C. It was found that 5, 10 min at room temperature
was optimum for clemastine, moxepril HCl, respectively for
Table 4 Determination of clemastine hydrogen fumarate, desloratadine, losartan potassium and moxepril HCl by eosin method
compared with ofﬁcial or reported methods.
Drug Eosin method Oﬃcial or reported methods
Clemastine hydrogen fumarate Mean ± R.S.D 100.24 ± 0.629 99.74 ± 0.452 (Rahman and Rahman, 2011)
Variance 0.4 0.2
Student-t-test 1.23 (1.86)a –
F-test 1.96 (5.14)a –
n 7 3
Desloratadine Mean ± R.S.D 100.02 ± 0.848 99.76 ± 1.03 (Nahed et al., 2007)
Variance 0.72 1.06
Student-t-test 0.536 (1.77)a –
F-test 1.46 (3.86)a –
n 8 7
Losartan potassium Mean ± R.S.D 99.89 ± 0.722 99.62 ± 0.823 (Ibrahim, 2005)
Variance 0.52 0.67
Student-t-test 0.524 (1.86)a –
F-test 1.29 (5.14)a –
n 7 3
Moxepril HCl Mean ± R.S.D 100.14 ± 0.751 99.86 ± 0.66 (Erturk et al., 2003)
Variance 0.57 0.44
Student-t-test 0.86 (1.74)a –
F-test 1.28 (3.22)a –
n 9 10
British Pharmacopoeia recommended non aqueous titration for clemastine using 0.1 M perchloric acid with potentiometric determination of the
end-point (Rahman and Rahman, 2011).
Spectrophotometric determination of desloratadine, losartan and moxepril through its reaction with NBD-Cl, TCNQ or through derivative
spectrophotometry, respectively (Nahed et al., 2007; Ibrahim, 2005; Erturk et al., 2003).
a The ﬁgures in parenthesis are the theoretical values for t- and F-tests (p< 0.05).
S546 S.S. Abd El-Hay et al.production of maximum absorbance. In case of desloratadine,
the maximum increase in absorbance was observed after
10 min at 50 C then decreased gradually. In the case of losar-
tan potassium, a gradual increase in absorbance was observed
till it reached maximum after 5 min at 60 C as seen in Fig. 4.
3.5. Effect of order of addition of reactants,
The most favorable sequence is drug-eosin-buffer-surfactant
for drugs (I), (II) and (III) while drug-eosin-surfactant-buffer
for (IV) to attain the highest color intensity and more stability.
There was less than a 1.0% variation in absorbance of all
formed complexes during the ﬁrst 45 min. of measurement
and remained stable for at least 1 h for all the studied drugs
(Fig. 5).
3.6. Composition of the ion-pair complexes
The composition of the ion-pair was studied by Job’s method
of continuous variation (Rose, 1964) and was found to be 1:1
for (I), (III) and (IV) while 1:2 for (II) with eosin (Fig. 6).
4. Method validation
Under the described experimental conditions, standard cali-
bration curves for, clemastine hydrogen fumarate, deslorata-
dine, losartan potassium and moxepril HCl with eosin were
constructed by plotting absorbance against concentration.
Conformity with Beer’s law was evident in the concentra-
tion range of the ﬁnal dilution cited in Table 1. The linearregression equation for each drug was listed in Table 1. The
correlation coefﬁcient was 0.9998–0.9999 indicating good
linearity.
5. Analytical applications
The proposed method was applied to determine the studied
drugs in their pharmaceutical dosage forms. Satisfactory re-
sults were obtained. To check the validity of the proposed
method, the standard addition technique was applied by add-
ing them to the analyzed pharmaceutical dosage forms.
The recovery of each drug was calculated by comparing the
concentration obtained from the spiked mixtures with those of
the drug. The results of analysis of the commercial dosage
forms and the recovery study are shown in Tables 2 and 3.
The results obtained were compared with the ofﬁcial and re-
ported methods (Nahed et al., 2007; Ibrahim, 2005; Erturk
et al., 2003; British Pharmacopoeia, 2007). Statistical compar-
ison of the results was performed with regard to accuracy and
precision using Student-t-test and F-ratio at 95% conﬁdence
level (Table 4). No signiﬁcant differences were found between
the proposed methods and ofﬁcial or reported methods.
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